Universal Beteiligungs und Servicegesellschaft mbH Raises Holdings in Align Technology, Inc. $ALGN

Universal Beteiligungs und Servicegesellschaft mbH grew its holdings in Align Technology, Inc. (NASDAQ:ALGN) by 6.3% in the 2nd quarter, Holdings Channel reports. The institutional investor owned 161,407 shares of the medical equipment provider’s stock after buying an additional 9,524 shares during the quarter. Universal Beteiligungs und Servicegesellschaft mbH’s holdings in Align Technology were worth $30,559,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently modified their holdings of ALGN. True Wealth Design LLC grew its holdings in Align Technology by 7,650.0% during the second quarter. True Wealth Design LLC now owns 155 shares of the medical equipment provider’s stock worth $29,000 after acquiring an additional 153 shares during the period. Cromwell Holdings LLC boosted its position in shares of Align Technology by 2,900.0% during the 2nd quarter. Cromwell Holdings LLC now owns 180 shares of the medical equipment provider’s stock worth $34,000 after purchasing an additional 174 shares in the last quarter. SVB Wealth LLC acquired a new position in shares of Align Technology during the 1st quarter worth $36,000. Farther Finance Advisors LLC increased its holdings in shares of Align Technology by 42.2% in the 2nd quarter. Farther Finance Advisors LLC now owns 310 shares of the medical equipment provider’s stock valued at $59,000 after purchasing an additional 92 shares in the last quarter. Finally, Assetmark Inc. lifted its stake in shares of Align Technology by 327.6% in the second quarter. Assetmark Inc. now owns 449 shares of the medical equipment provider’s stock valued at $85,000 after purchasing an additional 344 shares during the period. 88.43% of the stock is currently owned by hedge funds and other institutional investors.

Align Technology Stock Down 3.3%

Shares of NASDAQ:ALGN opened at $132.61 on Tuesday. The company has a market capitalization of $9.51 billion, a P/E ratio of 25.70, a P/E/G ratio of 1.49 and a beta of 1.84. The stock’s fifty day simple moving average is $132.83 and its 200-day simple moving average is $158.73. Align Technology, Inc. has a 52-week low of $122.00 and a 52-week high of $246.19.

Align Technology (NASDAQ:ALGN) last released its quarterly earnings results on Wednesday, October 29th. The medical equipment provider reported $2.61 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.38 by $0.23. The company had revenue of $995.69 million for the quarter, compared to analysts’ expectations of $980.75 million. Align Technology had a net margin of 9.50% and a return on equity of 14.06%. The firm’s revenue for the quarter was up 1.8% compared to the same quarter last year. During the same period last year, the company earned $2.35 EPS. Align Technology has set its Q4 2025 guidance at EPS. On average, sell-side analysts anticipate that Align Technology, Inc. will post 7.98 earnings per share for the current year.

Align Technology declared that its Board of Directors has authorized a share repurchase program on Tuesday, August 5th that allows the company to buyback $200.00 million in outstanding shares. This buyback authorization allows the medical equipment provider to buy up to 2% of its shares through open market purchases. Shares buyback programs are often an indication that the company’s leadership believes its stock is undervalued.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on ALGN shares. Wall Street Zen upgraded shares of Align Technology from a “hold” rating to a “buy” rating in a research report on Saturday, November 8th. Wells Fargo & Company lowered their price target on Align Technology from $199.00 to $181.00 and set an “overweight” rating on the stock in a report on Thursday, October 30th. Needham & Company LLC reaffirmed a “hold” rating on shares of Align Technology in a research note on Thursday, October 30th. Weiss Ratings downgraded Align Technology from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Wednesday, October 8th. Finally, UBS Group lowered their target price on Align Technology from $160.00 to $155.00 and set a “neutral” rating on the stock in a report on Thursday, October 16th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, seven have given a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $175.45.

Align Technology Company Profile

Align Technology, Inc designs, manufactures, and markets Invisalign clear aligners, and iTero intraoral scanners and services for orthodontists and general practitioner dentists in the United States, Switzerland, and internationally. The company's Clear Aligner segment offers comprehensive products, including Invisalign comprehensive package that addresses the orthodontic needs of younger patients, such as mandibular advancement, compliance indicators, and compensation for tooth eruption; and Invisalign First Phase I and Invisalign First Comprehensive Phase 2 package for younger patients generally between the ages of six and ten years, which is a mixture of primary/baby and permanent teeth.